Richard Durbin actually said...
I'm also very interested to learn more about the FTC's efforts to address anticompetitive pay-for-delay patent settlements, which keep lower-cost generic drugs off the market and cost consumers and taxpayers billions of dollars.
Context
Durbin highlights concerns over patent settlements affecting drug prices.
03/17/2010